Clinical Trials Logo

Filter by:
NCT ID: NCT00162240 Completed - Diabetes Mellitus Clinical Trials

PPAR - Combination With Metformin

Start date: June 2003
Phase: Phase 3
Study type: Interventional

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT ID: NCT00161993 Completed - Clinical trials for Primary Immunodeficiency Diseases (PID)

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)

Start date: June 13, 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglobulinemia. Subjects are treated every 21 days and receive a total of 12 infusions: for the first 3 infusions subjects receive GAMMAGARD S/D to ensure a steady-state and to acquire data with a licensed product; for the remaining 9 infusions subjects receive IGIV, 10% TVR Solution.

NCT ID: NCT00161655 Completed - Psoriasis Clinical Trials

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

NCT ID: NCT00160524 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

PRECiSE 3
Start date: July 2004
Phase: Phase 3
Study type: Interventional

An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).

NCT ID: NCT00160186 Completed - Gastrectomy Clinical Trials

Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate BMI and the nutritional parameters of Creon (pancreatin) versus placebo after a total or subtotal gastrectomy.

NCT ID: NCT00160160 Completed - Hypertension Clinical Trials

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

Start date: October 2004
Phase: N/A
Study type: Interventional

This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

NCT ID: NCT00160082 Completed - Clinical trials for Post Polio Syndrome, PPS

Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)

Start date: January 2001
Phase: N/A
Study type: Interventional

The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to placebo on functional balance, activity patterns, pain, fatigue, sleep, vitality, muscular strength, pulmonary capacity, walking ability, balance and safety.

NCT ID: NCT00159913 Completed - Clinical trials for Pulmonary Arterial Hypertension, Children

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

Start date: August 2003
Phase: Phase 3
Study type: Interventional

This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil.

NCT ID: NCT00159887 Completed - Clinical trials for Pulmonary Hypertension

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

Start date: December 2002
Phase: Phase 3
Study type: Interventional

Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension

NCT ID: NCT00159874 Completed - Clinical trials for Pulmonary Arterial Hypertension

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

Start date: January 2004
Phase: Phase 3
Study type: Interventional

Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.